Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Japan, June 2, 2009 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter “Astellas”)today announced that the prevention of peptic ulcers in uses of...
Japan, May 13, 2009 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) today announced that at the meeting of the Board of...
Japan, May 13, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called “the Company”) today announced that at the meeting of the Board of...
Read more about Astellas Announces Cancellation of Treasury Stock
Japan, April 27, 2009 - Astellas Pharma Inc. ("the Company"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has decided to nominate two candidates of outside...
Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo: Chairman & President: Dr. Thomas Heil) and Astellas Pharma Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi...
Read more about MICOMBI® Combination Tablets approved for manufacturing and marketing
Japan, April 7, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that it has decided to construct Fermentation Technology...
Japan, April 6, 2009 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc. (“Astellas”; headquarters:...
Read more about Launch of the Osteoporosis Treatment, RECALBON® Tablets / Bonoteo® Tablets
Tokyo, Japan, March 16, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that it will terminate its $16.00 per share offer for CV Therapeutics, Inc. (Nasdaq: CVTX) and will not...
Read more about ASTELLAS TO TERMINATE OFFER FOR CV THERAPEUTICS
Tokyo, Japan, March 6, 2009 – Astellas Pharma Inc. today announced that its wholly owned subsidiary, Astellas US Holding, Inc., will nominate two directors for election to the Board of Directors...
Follow us
